Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zydus Cadila’s net sales was up by 21% year on year from INR9126m to INR11063m, on a consolidated basis, for the second quarter ended 30 September 2010.
Subscribe to our email newsletter
Net profit was up by 30% to INR1708m from INR1319m last year.
During the quarter, Zydus Cadila’s revenues were driven by 35% growth in the global formulations business, 19% year on year growth in domestic formulations and 41% year on year growth in the US business.
Formulations business in Brazil grew by 27%. The wellness business posted a growth of 23%.
During the quarter, Zydus Nycomed, the group’s joint venture company with Nycomed, commissioned its newly expanded API manufacturing facility at Navi Mumbai, India.
The plant earlier provided high quality Key Starting Materials (KSMs) for manufacturing Pantoprazole.
Besides other APIs, the expanded facility will now manufacture the active ingredient of Pantoprazole for Nycomed.